uniQure (NASDAQ:QURE) Sees Unusually-High Trading Volume

uniQure (NASDAQ:QURE) shares saw unusually-high trading volume on Thursday . Approximately 13,346 shares changed hands during trading, a decline of 97% from the previous session’s volume of 488,377 shares.The stock last traded at $30.59 and had previously closed at $30.31.

QURE has been the topic of a number of research analyst reports. Chardan Capital restated a “buy” rating and set a $95.00 price objective (down from $100.00) on shares of uniQure in a report on Tuesday, July 27th. Credit Suisse Group reiterated an “outperform” rating and issued a $27.46 price target (down from $78.00) on shares of uniQure in a research note on Tuesday, July 27th. SVB Leerink reiterated a “buy” rating on shares of uniQure in a research note on Tuesday, September 14th. Zacks Investment Research lowered shares of uniQure from a “buy” rating to a “hold” rating in a research note on Thursday, September 30th. Finally, TheStreet upgraded shares of uniQure from a “d-” rating to a “c” rating in a research note on Monday, July 26th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $58.04.

The business’s 50-day moving average price is $31.66 and its 200 day moving average price is $31.95. The company has a market cap of $1.42 billion, a P/E ratio of 4.81 and a beta of 1.22. The company has a debt-to-equity ratio of 0.11, a quick ratio of 15.06 and a current ratio of 15.06.

uniQure (NASDAQ:QURE) last announced its earnings results on Sunday, July 25th. The biotechnology company reported $8.51 EPS for the quarter, topping the consensus estimate of $2.97 by $5.54. The business had revenue of $463.87 million during the quarter, compared to the consensus estimate of $212.65 million. uniQure had a net margin of 60.66% and a return on equity of 90.98%. Equities research analysts forecast that uniQure will post 6.23 earnings per share for the current year.

In other uniQure news, insider Ricardo Dolmetsch sold 8,603 shares of uniQure stock in a transaction dated Thursday, September 16th. The shares were sold at an average price of $37.10, for a total value of $319,171.30. Following the completion of the sale, the insider now owns 69,126 shares in the company, valued at approximately $2,564,574.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Alexander Edward Kuta III sold 6,000 shares of uniQure stock in a transaction dated Monday, August 16th. The stock was sold at an average price of $28.84, for a total transaction of $173,040.00. The disclosure for this sale can be found here. Insiders have sold a total of 29,732 shares of company stock valued at $1,047,903 in the last ninety days. 2.68% of the stock is currently owned by insiders.

Institutional investors have recently modified their holdings of the business. Dark Forest Capital Management LP acquired a new stake in uniQure in the 2nd quarter worth about $27,000. Bank of Montreal Can raised its stake in uniQure by 131.0% in the 1st quarter. Bank of Montreal Can now owns 1,102 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 625 shares in the last quarter. Lazard Asset Management LLC raised its stake in uniQure by 2,292.6% in the 1st quarter. Lazard Asset Management LLC now owns 1,938 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 1,857 shares in the last quarter. Advisory Services Network LLC acquired a new position in shares of uniQure in the 2nd quarter valued at approximately $82,000. Finally, KB Financial Partners LLC acquired a new position in shares of uniQure in the 1st quarter valued at approximately $90,000. Institutional investors and hedge funds own 77.06% of the company’s stock.

About uniQure (NASDAQ:QURE)

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Featured Article: Death Cross

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.